Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This dose-escalation study is aimed at investigating a novel application for artesunate in
the treatment of Friedreich ataxia. It will evaluate this novel application of oral
artesunate using a surrogate biological marker as primary endpoint in a phase I-II open trial